Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rockwell Medical (RMTI) EBITDA Margin (2016 - 2026)

Rockwell Medical filings provide 16 years of EBITDA Margin readings, the most recent being 2.17% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 7.0% to 2.17% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.77%, a 737.0% decrease, with the full-year FY2025 number at 6.77%, down 737.0% from a year prior.
  • EBITDA Margin hit 2.17% in Q4 2025 for Rockwell Medical, up from 9.95% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.84% in Q3 2024 to a low of 54.52% in Q4 2021.
  • Median EBITDA Margin over the past 5 years was 9.17% (2025), compared with a mean of 17.58%.
  • Biggest five-year swings in EBITDA Margin: soared 4434bps in 2022 and later plummeted -1678bps in 2025.
  • Rockwell Medical's EBITDA Margin stood at 54.52% in 2021, then skyrocketed by 81bps to 10.18% in 2022, then skyrocketed by 76bps to 2.48% in 2023, then rose by 15bps to 2.1% in 2024, then dropped by -3bps to 2.17% in 2025.
  • The last three reported values for EBITDA Margin were 2.17% (Q4 2025), 9.95% (Q3 2025), and 8.39% (Q2 2025) per Business Quant data.